5th How to Diagnose and Treat Acute Leukaemias #ESHAL2026

Conference Details

Date: 27 February 2026

Time: 08:00

Duration: 3 days

Location: Mandelieu-La Napoule, France

Cost: € 300 - € 600

Organiser: ESH - European School of Haematology

Conference Website

Conference Description

ABOUT THE CONFERENCE:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address up to date diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. Intensive interaction between the speakers and participants will be helpful in spreading knowledge.

Novel and still evolving insights into the biology and diagnosis of acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease. Recently updates on prognostication and classification of acute leukaemias have been published which will be discussed in various sessions.

The programme of this “How to Diagnose and Treat: Acute Leukaemias” includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.

CONFERENCE MAIN SCIENTIFIC TOPICS:

• Dilemmas in acute leukaemias;
• Novel treatments;
• Diagnosis and treatment of rare diseases and rare subsets;
• Is MRD a proper surrogate endpoint in AML?
• Optimizing outcomes in acute leukemias using supportive strategies;
• Immune targeting strategies in ALL;
• Real-world AML therapy;
• Is Blina-TKI is enough to cure Ph-positive ALL?
• HSC transplantation;
• Leukemia treatment challenges.

LEARNING OBJECTIVES:

• Knowledge of Classification of ALL and AML;
• Insight in prognosis of ALL and AML;
• Application of MRD;
• Knowledge of established and novel treatment options in ALL and AML;
• Indications of alloSCT;
• Management of challenging subgroups of AML and ALL;
• Controversies on clinical trials and treatment options.

The programme will include:

• Plenary Sessions;
• Interactive Case Presentations;
• Roundtables;
• Panel Discussions;
• Debates;
• Poster Walks;
• Meet the Expert Sessions;
• Voting technology;
• Ample time for in-depth discussion.

This conference is a Face to Face meeting. No virtual attendance is scheduled.